

Media Release

Contact:

Kenn Israel
Vice President of Marketing
Robinson Pharma Inc.
Phone: 714 241 0235 FAX: 714 751 6066
Email: KIsrael@RobinsonPharma.com

January 2, 2012

FOR IMMEDIATE RELEASE

Drug Manufacturing License issued to Robinson Pharma Inc.

January 2, 2012 – Santa Ana CA. – **The State of California, Department of Public Health, Food and Drug Branch, after a thorough and complete audit of the softgel manufacturing facilities of Robinson Pharma Inc. (RPI), have determined that the operations, facilities, and staff qualifications of RPI are compliant with standards for the grant of a Drug Manufacturing License and have issued License Number 55939 to RPI. The facility is also registered with the U.S. Food and Drug Administration pursuant to Part 207 of Title 21, U.S. Code of Federal Regulation.**

Achieving this major quality benchmark caps a terrific year for Robinson Pharma and will enable the company to begin OTC and prescription drug manufacturing in 2012. RPI has focused on incremental quality improvement and has progressed steadily to become one of the most extensively certified manufacturers of nutritional and pharmaceutical products. Presently RPI maintains third party certifications from NPA, NSF, STR, and participates in the USP Verified Program for Dietary Supplements.

RPI began its pharmaceutical manufacturing initiative one year ago with the expressed goal to obtain a drug manufacturing license during 2011. Achieving this goal required extensive investment in facility upgrades, new equipment, and dedicated staffing. "I am very pleased with the rapid progress towards this important benchmark," stated founder and CEO, Tuong Nguyen. "We as a team understand compliance with this standard from both an operational and infrastructure perspective has improved our overall functional competence and has positive spill over benefits to our entire organization. The process of obtaining a drug license has changed our culture for the better."

“The requirements of pharmaceutical manufacturing demanded the largest incremental steps our company has taken on the quality improvement path that that we initiated some 4 years ago. As a team we think about the manufacturing process differently than before, the perspective is more rigorous, makes many fewer assumptions, and demands greater precision and control,” stated Fred Jamee, Senior VP of Quality and Compliance. “Obtaining this license is the first major benchmark accomplished by our pharmaceutical operations group. We expect additional achievements in 2012”

Robinson Pharma Inc. (RPI) is a minority owned, Southern California based, drug licensed, full service provider of private label, store brand, and contract manufacturing services for dietary supplements. RPI features the largest soft gel encapsulation capacity in the U.S. with 22 continuous dry encapsulation lines capable of producing over 12 billion soft gels per year. Production capabilities include tablet compression, capsule filling, enteric coating of soft gels and tablets, custom imprinting, and a range of packaging options including bottles, blister packaging boxing, and bulk product. Additional services include product development and ingredient sourcing. Robinson Pharma Inc. provides rapid turnaround on all projects and offers highly competitive pricing. Robinson Pharma Inc. maintains 400,000 square feet of production, operations, and warehousing facilities. For more information please email Sales@RobinsonPharma.com, Phone (714) 241-0235 or visit www.RobinsonPharma.com